FDA
-
-
-
-
-
-
-
Intellia reports positive phase 3 results for gene editing HAE treatment
-
-
-
-
-
-
-
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
-
-
-
-
-
-
-
William Blair Upgrades Intellia Therapeutics (NTLA) to Outperform
-
-
-
-
-
-
-
FDA lifts clinical hold on Intellia's ATTRv-PN gene therapy trial
-
-
-
-
-
-
-
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on Intellia Therapeutics (NTLA)
-
-
-
-
-
-
-
Bernstein on Intellia Therapeutics (NTLA): 'Investor Perception Takes Another Big Hit'
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

